



# RHEUMATOID ARTHRITIS ENROLLMENT & PRESCRIPTION FORM

PHONE: 800-641-8475 FAX: 800-530-8589 WEB: www.HealthDyneSpecialty.com

To submit a new prescription via eRx, use NPI 1902298805. Faxed prescriptions will only be accepted from prescribing practitioners. Patients may not submit prescriptions via fax and must submit original copies in person or via the mail. Prescribers are reminded patients may choose any pharmacy of their choice.

<b>PATIENT INFORMATION</b>	Patient: _____ Caregiver: _____
	DOB: _____ Male Female Weight: _____ kgs or lbs (check one) Height: _____ in or cm (check one) Recorded Date: _____
	Address: _____ City: _____ State: _____ Zip: _____
	Best Phone #: _____ Cell Alternate Phone #: _____ Cell Email: _____
	Allergies: _____ Latex Allergy: Yes No
	ICD-10 Code for requested therapy: _____ ICD-10 Code(s) for other medical conditions: _____

## PLEASE FAX COPY OF ALL INSURANCE CARDS (FRONT & BACK) INCLUDING MEDICAL AND PRESCRIPTION

<b>MEDICAL ASSESSMENT</b>	Date of Diagnosis or Years with Disease: _____
	PRIOR MEDICATIONS: Acetaminophen, ibuprofen, naproxen, aspirin Humira Enbrel Methotrexate Corticosteroids Celebrex Indocin Azulfidine Other meds tried: _____ Add'l justification for med: _____
	CURRENT MEDICATIONS: _____ Is patient also taking methotrexate? Yes No
	Date of Negative TB Test: _____ Hep B ruled out: Yes No If no, treatment started?: Yes No

## PLEASE PROVIDE ALL CLINICAL INFORMATION INCLUDING LAB RESULTS ON ALL FORMS

<b>PRESCRIPTION INFORMATION</b>	<b>MEDICATION</b>	<b>DOSE/STRENGTH</b>	<b>DIRECTIONS</b>	<b>QUANTITY</b>	<b>REFILLS</b>
		Actemra®	162 mg/0.9 mL Prefilled Syringe Actemra Actpen 162 mg/0.9 mL	162 mg Sub-Q every other week 162 mg Sub-Q once a week	2 PFS/pens      4 PFS/Pens
	Cimza®	Starter Dose: Starter Kit (200 mg prefilled Syringes)	400mg Sub-Q at weeks 0, 2, and 4	1 Kit = 6 x 200 mg/mL PFS 3 Kits = 3 cartons of 2 x 200 mg vials	_____
		Maintenance Dose: 200mg/mL Prefilled Syringe 200mg Lyophilized Vial	400mg Sub-Q every 4 weeks 200mg Sub-Q every 2 weeks	1 Carton = 2 x 200 mg/mL PFS 1 Carton = 2 x 200 mg vials	_____
	Enbrel®	50mg/mL Sureclick™ 50mg/mL Prefilled Syringe 25mg Vial (inj. supplies incl) 25mg/mL Prefilled Syringe Enbrel Mini Cartridge 50mg/mL	Inject 50mg Sub-Q ONCE a week Inject 25mg Sub-Q TWICE a week _____	1 Kit (weekly dosing) 2 Kits (twice weekly dosing)	_____
	Humira®	40mg/0.8mL PEN 40mg/0.8mL Prefilled Syringe 40mg/0.4mL PEN (Citrate Free) 40mg/0.4mL Prefilled Syringe (Citrate Free) 20mg/0.2mL Prefilled Syringe (Citrate Free) 10mg/0.1mL Prefilled Syringe (Citrate Free) 10mg/0.2mL Prefilled Syringe 20mg/0.4mL Prefilled Syringe 80mg/0.8mL PEN	Inject 40mg Sub-Q every OTHER week Inject 40mg Sub-Q ONCE a week 80mg Sub-Q every OTHER week.	# _____ of PFS # _____ of Pens	_____
	Kevzara®	150mg/1.14mL Pen 150mg/1.14mL Prefilled Syringe 200mg/1.14mL Pen 200mg/1.14mL Prefilled Syringe	150mg Sub-Q every 2 week 200mg Sub-Q every 2 weeks	2 Pens 2 PFS	_____
	Olumiant®	1mg 2mg	1 tablet by mouth once daily 1 tablet by mouth once daily	30 30	_____
	Orencia®	250mg Vial (IV use only)	_____ mg/kg IV every month	2 Vials      3 Vials      4 Vials	_____
		125mg/mL Prefilled Syringe 250mg Vial (IV use only) 125mg/mL Clickject PEN 50mg/0.4mL Prefilled Syringe 87.5mg/0.7mL Prefilled Syringe	125mg Sub-Q ONCE a week _____ mg IV infusion over 30 minutes every 2 weeks for 3 doses (i.e., a dose at weeks 0, 2, and 4). Starting at week 8, give _____ mg IV infusion over 30 minutes every 4 weeks.	# _____ of PFS # _____ of Pens # _____ of Vials	_____
	Otrexup®	10mg/0.4mL Autoinjector 12.5mg/0.4mL Autoinjector 15mg/0.4mL Autoinjector 17.5mg/0.4mL Autoinjector 20mg/0.4mL Autoinjector 22.5mg/0.4mL Autoinjector 25mg/0.4mL Autoinjector 7.5mg/0.4mL Autoinjector	1 Autoinjector one time weekly	4 Autoinjectors	_____



# RHEUMATOID ARTHRITIS ENROLLMENT & PRESCRIPTION FORM

PHONE: 800-641-8475 FAX: 800-530-8589 WEB: www.HealthDyneSpecialty.com

To submit a new prescription via eRx, use NPI 1902298805. Faxed prescriptions will only be accepted from prescribing practitioners. Patients may not submit prescriptions via fax and must submit original copies in person or via the mail. Prescribers are reminded patients may choose any pharmacy of their choice.

Patient: \_\_\_\_\_ DOB: \_\_\_\_\_

PRESCRIPTION INFORMATION	MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
	Rasuvo®	_____	1 Autoinjector one time weekly	4 Autoinjectors	_____
	Remicade®	100 mg Lyophilized Vial(s)	_____ mg/kg IV every two months Starter doses: _____ mg/kg IV at 0,2, and 6 weeks for induction Every 6 weeks (5mg/kg q 6 weeks)	_____ Vial(s)	_____
	Rinvoq®	15mg ER Tablet	Take 1 tablet by mouth once daily	30	_____
	Rituxan®	100mg/10mL Vial 500mg/10mL Vial	1000mg IV on days 1 and 15 every _____ weeks	_____ Vial(s)	_____
	Simlandi®	40mg/0.4mL (PEN) 40mg/0.4mL (PFS)			_____
	Simponi®	50 mg/0.5mL SmartJect™ 50 mg/0.5mL Prefilled Syringe	Inject 1 dose (50mg) Sub-Q once monthly	1 (one)	_____
	Simponi® Aria™	Starter Dose: 50mg (4mL) Vial(s)	2 mg/kg IV infusion over 30 min at week 0	_____ Vial(s)	_____
		Maintenance Dose: 50mg (4mL) Vial(s)	2 mg/kg IV infusion over 30 min at week 4 and every 8 weeks thereafter	_____ Vial(s)	_____
	Truxima®	100mg/10mL Vial 500mg/50mL Vial	1000mg IV on days 1 and 15 every _____ weeks	_____ Vial(s)	_____
Xeljanz®	5 mg tablet XR 11mg	Take 1 tablet by mouth twice daily Take 1 tablet by mouth one time daily	60 Tablets 30 Tablets	_____ _____	
Other					

PRESCRIBER INFORMATION	INJECTION TRAINING:	OFFICE TO COORDINATE	HEALTHDYNE SPECIALTY TO COORDINATE
	Anticipated Start Date: _____	Prescriber Specialty: _____	
	Ship to: Patient Physician Clinic Other: _____		
	Fax #: _____	Contact Name: _____	
	Office Address: _____	City: _____	State: _____ Zip: _____
	The terms and conditions posted at www.HealthDyneSpecialty.com have been read by the person signing this form and are incorporated into this document by reference. The data privacy terms posted at www.HealthDyneSpecialty.com have been read by the person signing this form and are incorporated into this document by reference.		
	I understand that HealthDyne Specialty may transfer this prescription to another pharmacy as an agent of the prescriber if unable to dispense.		
	Prescriber's Name: _____	Prescriber's Signature: _____	Date: _____
	Use substitution	Dispense as written	

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling (800)-641-8475 to obtain instructions as to the proper destruction of the transmitted material.